Results 181 to 190 of about 208,148 (266)

Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases. [PDF]

Ann Hematol
Yousefi A, Levin MD, Cornelissen JJ, Westerweel PE.   +3 more
europepmc   +1 more source

Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature. [PDF]

Open Med (Wars)
Zhang Y, Li A.
europepmc   +1 more source

Allele-Specific PCR for Detection of Missense Mutations in the Chimeric <i>BCR::ABL1</i> Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients. [PDF]

Int J Mol Sci
Skripkina A, Fevraleva I, Kuzmina E, Biderman B, Stepanova E, Chelysheva E, Turkina A, Sudarikov A.   +7 more
europepmc   +1 more source

Oncogenic gene fusions in cancer: from biology to therapy. [PDF]

Signal Transduct Target Ther
Liu SV, Nagasaka M, Atz J, Solca F, Müllauer L.   +4 more
europepmc   +1 more source

An overview of chronic myeloid leukemia and its animal models [PDF]

, 2015

core   +1 more source

Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population. [PDF]

Hematol Oncol
Breccia M, Rossi AR, Giai V, Martino B, Fava C, Annunziata M, Abruzzese E, Binotto G, Baratè C, Nardozza AP, Misto A, Coco P, Calafiore V, Carraro MC, Cattina F, Cavazzini F, Corsetti MT, Crucitti L, Crugnola M, Di Veroli A, Ditonno P, Ermacora A, Ferrara F, Genua A, Gozzini A, Impera S, Iurlo A, Levato L, Luciano L, Miggiano MC, De Gobbi M, Santoro M, Scappini B, Scortechini AR, Patriarca A, Rosati S, Russo S, Sancetta R, Sanpaolo G, Santeramo TM, Sibilla S, Sorà F, Sportoletti P, Stagno F, Trabacchi E, Castagnetti F.   +45 more
europepmc   +1 more source

Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia. [PDF]

Int J Mol Sci
Stagno F, Russo S, Murdaca G, Mirabile G, Alvaro ME, Nasso ME, Zemzem M, Gangemi S, Allegra A.   +8 more
europepmc   +1 more source

Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study. [PDF]

Front Immunol
Wen Z, Liu Z, Ye X, Fan Z, Lin R, Huang F, Xuan L, Li X, Jin H, Dai M, Sun J, Zhou X, Wang Q, Liu X, Liu Q, Zhou H, Xu N.   +16 more
europepmc   +1 more source

KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3⁺ blast phase chronic myeloid leukemia. [PDF]

Mol Cancer
Kwon HJ, Shin JE, Khan A, Park SY, Kim J, Lee JY, Lee D, Lee S, Im CY, Moon H, Han YR, Tamai M, Akahane K, Inukai T, Lee W, Kim H, Kim HN, Ahn SM, Park HW, Kim DW.   +19 more
europepmc   +1 more source

Homoharringtonine: mechanisms, clinical applications and research progress. [PDF]

Front Oncol
Wang W, He L, Lin T, Xiang F, Wu Y, Zhou F, He Y.   +6 more
europepmc   +1 more source